Cargando…

Comparison of Nine Tools for Screening Drug-Drug Interactions of Oral Oncolytics

Patients with cancer are an especially vulnerable population to potential drug-drug interactions (DDIs). This makes it important to adequately screen them for DDIs. The objective of this study was to compare the abilities of nine DDI screening tools to detect clinically relevant interactions with or...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcath, Lauren A., Xi, Jingyue, Hoylman, Emily K., Kidwell, Kelley M., Kraft, Shawna L., Hertz, Daniel L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797246/
https://www.ncbi.nlm.nih.gov/pubmed/29787332
http://dx.doi.org/10.1200/JOP.18.00086
_version_ 1784860652224905216
author Marcath, Lauren A.
Xi, Jingyue
Hoylman, Emily K.
Kidwell, Kelley M.
Kraft, Shawna L.
Hertz, Daniel L.
author_facet Marcath, Lauren A.
Xi, Jingyue
Hoylman, Emily K.
Kidwell, Kelley M.
Kraft, Shawna L.
Hertz, Daniel L.
author_sort Marcath, Lauren A.
collection PubMed
description Patients with cancer are an especially vulnerable population to potential drug-drug interactions (DDIs). This makes it important to adequately screen them for DDIs. The objective of this study was to compare the abilities of nine DDI screening tools to detect clinically relevant interactions with oral oncolytics. METHODS: Subscription-based tools (ie, PEPID, Micromedex, Lexicomp, Facts & Comparisons) and free tools (ie, Epocrates Free, Medscape, Drugs.com, RxList, WebMD) were compared for their abilities to detect clinically relevant DDIs for 145 drug pairs including an oral oncology agent. Clinical relevance was determined by a pharmacist using Stockley’s Drug Interactions. Descriptive statistics were calculated for each tool, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), and then compared grouped by free or subscription-based tools for the secondary analysis and analyzed via generalized estimating equations. RESULTS: For individual metrics, PPV had overall higher values (0.88 to 0.97) relative to the low values included for sensitivity (0.65 to 0.96), specificity (0.53 to 0.93) and NPV (0.38 to 0.83). The top-performing subscription and free tools, Lexicomp and Drugs.com, had no statistically significant differences in performance. Overall, subscription tools had a significantly higher sensitivity (0.85 ± 0.017 v 0.78 ± 0.017; P = .0082) and NPV (0.57 ± 0.039 v 0.48 ± 0.032; P = .031) than free tools. No differences were observed between the specificity and PPV. CONCLUSION: Due to the low performance of some tools for sensitivity, specificity, and NPV, individual performance should be examined and prioritized on the basis of the intended use when selecting a DDI tool. If a strong-performing subscription-based tool is unavailable, a strong-performing free option, like Drugs.com, is available.
format Online
Article
Text
id pubmed-9797246
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-97972462022-12-29 Comparison of Nine Tools for Screening Drug-Drug Interactions of Oral Oncolytics Marcath, Lauren A. Xi, Jingyue Hoylman, Emily K. Kidwell, Kelley M. Kraft, Shawna L. Hertz, Daniel L. J Oncol Pract Original Contributions Patients with cancer are an especially vulnerable population to potential drug-drug interactions (DDIs). This makes it important to adequately screen them for DDIs. The objective of this study was to compare the abilities of nine DDI screening tools to detect clinically relevant interactions with oral oncolytics. METHODS: Subscription-based tools (ie, PEPID, Micromedex, Lexicomp, Facts & Comparisons) and free tools (ie, Epocrates Free, Medscape, Drugs.com, RxList, WebMD) were compared for their abilities to detect clinically relevant DDIs for 145 drug pairs including an oral oncology agent. Clinical relevance was determined by a pharmacist using Stockley’s Drug Interactions. Descriptive statistics were calculated for each tool, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), and then compared grouped by free or subscription-based tools for the secondary analysis and analyzed via generalized estimating equations. RESULTS: For individual metrics, PPV had overall higher values (0.88 to 0.97) relative to the low values included for sensitivity (0.65 to 0.96), specificity (0.53 to 0.93) and NPV (0.38 to 0.83). The top-performing subscription and free tools, Lexicomp and Drugs.com, had no statistically significant differences in performance. Overall, subscription tools had a significantly higher sensitivity (0.85 ± 0.017 v 0.78 ± 0.017; P = .0082) and NPV (0.57 ± 0.039 v 0.48 ± 0.032; P = .031) than free tools. No differences were observed between the specificity and PPV. CONCLUSION: Due to the low performance of some tools for sensitivity, specificity, and NPV, individual performance should be examined and prioritized on the basis of the intended use when selecting a DDI tool. If a strong-performing subscription-based tool is unavailable, a strong-performing free option, like Drugs.com, is available. American Society of Clinical Oncology 2018-06 2018-05-22 /pmc/articles/PMC9797246/ /pubmed/29787332 http://dx.doi.org/10.1200/JOP.18.00086 Text en Copyright © 2018 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Original Contributions
Marcath, Lauren A.
Xi, Jingyue
Hoylman, Emily K.
Kidwell, Kelley M.
Kraft, Shawna L.
Hertz, Daniel L.
Comparison of Nine Tools for Screening Drug-Drug Interactions of Oral Oncolytics
title Comparison of Nine Tools for Screening Drug-Drug Interactions of Oral Oncolytics
title_full Comparison of Nine Tools for Screening Drug-Drug Interactions of Oral Oncolytics
title_fullStr Comparison of Nine Tools for Screening Drug-Drug Interactions of Oral Oncolytics
title_full_unstemmed Comparison of Nine Tools for Screening Drug-Drug Interactions of Oral Oncolytics
title_short Comparison of Nine Tools for Screening Drug-Drug Interactions of Oral Oncolytics
title_sort comparison of nine tools for screening drug-drug interactions of oral oncolytics
topic Original Contributions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797246/
https://www.ncbi.nlm.nih.gov/pubmed/29787332
http://dx.doi.org/10.1200/JOP.18.00086
work_keys_str_mv AT marcathlaurena comparisonofninetoolsforscreeningdrugdruginteractionsoforaloncolytics
AT xijingyue comparisonofninetoolsforscreeningdrugdruginteractionsoforaloncolytics
AT hoylmanemilyk comparisonofninetoolsforscreeningdrugdruginteractionsoforaloncolytics
AT kidwellkelleym comparisonofninetoolsforscreeningdrugdruginteractionsoforaloncolytics
AT kraftshawnal comparisonofninetoolsforscreeningdrugdruginteractionsoforaloncolytics
AT hertzdaniell comparisonofninetoolsforscreeningdrugdruginteractionsoforaloncolytics